This issue chosen by the Editor of Intestinal Research is the multicenter, randomized, double-blind study to compare the efficacy of multimatrix mesalazine 2.4 g/day and 4.8 g/day with controlled-release mesalazine 2.25 g/day performed by Ogata H, et al. A higher dose of pH-dependent release controlled mesalamine (4.8 g/day) appeared to be of benefit in moderately active UC in the previous studies. Multimatrix mesalazine 4.8 g/day has higher efficacy and shows no difference in safety in mildly to moderately active UC, in comparison with pH-dependent-release mesalazine 3.6 g/day in the previous study of Ogata H, et al. This study reported that the change in UC-DAI in the multimatrix-4.8 group was greater than in the other low-dose treatment groups not only in moderately active UC (UC-DAI score at baseline: 6–10) but also in almost all subgroups, including disease type, location of colitis and mildly active UC with no associated safety concerns. Read more about the efficacy and safety of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day in ulcerative colitis. Best regards,